Please upgrade your browser.
In this Q&A article, Bradley McGregor, M.D., explains how combination therapy will have a global impact on patients.
Five years ago, Dawnia, who lives in Texas, was diagnosed with stage II kidney cancer at age 50. During a routine visit at her gynecologist’s office, the nurse practitioner was alarmed when she learned that Dawnia’s mother was recently diagnosed with kidney cancer. The nurse urged her to get an ultrasound which showed a 9×9 tumor. Dawnia credits her nurse practitioner’s suggestion of getting an ultrasound with saving her life. She has remained cancer-free following her nephrectomy. No chemotherapy or radiation was required. Dawnia had chest x-rays and abdominal CT scans every three to six months for two years as follow-up. If kidney cancer runs in your family, it is important to discuss it with your doctor so you can receive proper treatment.
People with advanced kidney cancer can skip surgery to have their kidneys removed and instead go right to drug treatment, a recent study showed.
According to a recent study by the University of Florida, a healthy organic diet that is rich in fruits, vegetables and dairy can help lower your cancer risk by 65 percent. The study also states that avoiding tobacco can help lower your risk of developing kidney cancer.
UNC scientists have discovered some really interesting information about how RCCC develops, providing new pathways for targeted therapies. Targeted therapies are those that work by zeroing in on a specific pathway in the cancer’s development. In this case, Qing Zhang, PhD, and his team of fellow scientists saw that in 90% of RCCC, an important tumor suppressor gene called VHL was either missing or malfunctioning. When this happens, a protein called ZHX2 accumulates in high quantities in the renal cells. The VHL gene loss is responsible in not only in the origination of the tumor(s), but also plays a key role in their development and metastasis, as the ZHX2 protein promotes blood vessel growth.
According to the University of Texas, 5-8% of RCC cases are hereditary.
Since 2006, the Kidney Cancer Association has supported an annual Young Investigator Award (YIA) through the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). The YIA supported by Kidney Cancer Association provides funding to promising doctors to pursue careers in kidney cancer research. This year, the Kidney Cancer Association supported two awards – a YIA and an ASCO Annual Meeting Merit Award – through the Conquer Cancer Foundation. The 2018 Conquer Cancer Foundation of ASCO/Kidney Cancer Association YIA recipient, Liam C. Macleod, M.D., M.P.H., is currently completing his second year of fellowship training at the University of Pittsburgh and received $50,000 from the Kidney Cancer Association for his research on regionalization and how it affects patients.
Immunotherapy to treat cancer has been around for a while, but new research is making headway in directions that are both exciting and are giving hope to patients fighting cancer. In this video, Dr Shubham Pant, an oncologist in Houston Texas, demystifies immunotherapy.
Dr. Kuzel discusses treatment options for metastatic RCC based on risk stratification. In the article, Dr. Kuzel talks about two different case scenarios.
Isaac Chan, a medical oncology fellow at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses a patient's right to refuse palliative care.
|Powered by NeonCRM|